Pharmaceutical company Endo International plc (NASDAQ:ENDP) reported on Friday the start of shipment of the authorised generic version of INVANZ (ertapenem for injection) in the US.
Par Pharmaceutical (Par), the company's operating subsidiary, has begun shipping the authorized generic version of Merck's INVANZ (ertapenem for injection) in the US following an exclusive US supply and distribution agreement with a subsidiary of Merck & Co Inc of Kenilworth, N.J.
For the 12 months ending 31 May 2018, the US sales of INVANZ were approximately USD390m, according to IQVIA data.
INVANZ is reportedly a registered trademark of Merck Sharp & Dohme Corp.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US